OXiGENE Announces Presentation at BIO CEO Conference on February 11th

        Print
| Source: OXiGENE, Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 16th annual BIO CEO & Investor conference on February 11, 2014 at 11:00 am ET at the Waldorf Astoria Hotel in New York City.

To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations." A replay of the webcast will be available one hour after the conclusion of the live event. 

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Investor and Media Contact:

650-635-7000